Secretive Moderna shared a new peek into its infectious disease vaccines efforts Thursday.
Marking a big step in its march toward potential approval, GlaxoSmithKline’s shingles vaccine candidate Shingrix won the support of an FDA panel.
Even as many on social media blasted Allergan’s licensing deal with the Saint Regis Mohawk Tribe, some industry-watchers think the tactic is bound to spread.
A phase 3 study shows that Seqirus' MF59-adjuvanted quadrivalent flu vaccine provides better protection in those younger than two years old.
Here's other vaccine news of note for this week.
PATH, Walter Reed and GSK have partnered to determine whether tweaking the regimen of Mosquirix could lead to better malaria protection.
Nonprofit PATH secured a major commitment from the Gates Foundation for its new vaccine group.
Gavi's vaccine initiative will have saved 20 million lives and $350 billion in healthcare costs by 2020, a recent study found.
Following a rush of news coverage into an unregulated human trial of a herpes vaccine in St. Kitts, the island’s government is launching a probe.